Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777274 | 0.78 | EPHX1 (0.38) | — | |
| SCHEMBL29952304 | 0.77 | LPL (0.46) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL17196246 | 0.77 | MGLL (0.53) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL852507 | 0.77 | LPL (0.46) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL15330762 | 0.76 | ENPP2 (0.42) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL27992019 | 0.75 | MGLL (0.53) | MGLLENPP2KDM4EALDH1A1 | |
| SCHEMBL3120299 | 0.74 | LPL (0.47) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL3290605 | 0.73 | ENPP2 (0.40) | MGLLENPP2KDM4EALDH1A1LPL | |
| SCHEMBL29534986 | 0.73 | TSHR (0.44) | KDM4EALDH1A1CA7CA14CA1 | |
| SCHEMBL28465416 | 0.73 | ALDH1A1 (0.32) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183775-B1 | SUBSTITUTED PHENYL SULFIDE COMPOUND AND APPLICATION THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-20230271919-A1 | SUBSTITUTED PHENYL SULFIDE COMPOUND AND APPLICATION THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4183775-A1 | SUBSTITUTED PHENYL SULFIDE COMPOUND AND APPLICATION THEREOF | Shenyang Sinochem Agrochemicals R & D Co., Ltd. (CN) | 2023-05-24 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271919-A1 | SUBSTITUTED PHENYL SULFIDE COMPOUND AND APPLICATION THEREOF | TYR, ARSA, TST | MGLL 1112/4885ENPP2 2429/4885KDM4E 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.